Targeted therapies, including BTK inhibitors and venetoclax, have replaced chemoimmunotherapy as the first-line standard for CLL, emphasizing patient preference and risk factors in treatment decisions ...

Combination therapies for chronic lymphocytic leukemia (CLL) offer improved depth of response and potentially longer survival times compared with single-agent treatments. They target different ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Chronic lymphocytic leukemia (CLL), is a type of cancer that affects a type of white blood cell in your body called a lymphocyte. White blood cells are made in your bone marrow and help your body ...

In the age of targeted therapy, what’s the best long-term strategy to treat chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries? Should treatment be continuous to achieve ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Four trials presented at the recent American Society of Clinical Oncology (ASCO) meeting showed promise of new drug combinations or monotherapies in treating chronic lymphocytic leukemia (CLL) and ...